We discussed the IGF-1 and cancer-surveillance conversation in the post on tesamorelin for visceral fat, and the same principles apply here
doi:10.1002/oby.20154 Mao T, Huang F, Zhu X, Wei D, Chen L
GLP-1 users frequently note their taste preferences have changed: and so flavour becomes really important
Given that there is no placebo-controlled human data, no established dose, and a mechanism whose foundational papers were retracted, an absence of noticeable effect is fully consistent with the current evidence it does not necessarily indicate a defective product, the wrong route, or an insufficient duration
10.1080/17512433.2020.1736041 73 SorribasM.CarnavalT.PelezN.SecanellaL.SalordS.SarretS.et al (2023)
One study tested 300 mg, 2x a day vs